On Mar. 20, 2023, some of the world’s leading makers of flu vaccines said they could make hundreds…
On Feb. 24, 2023, Moderna announced will make certain contingent development, commercial and regulatory milestone payments to the…
On Feb. 17, 2023, Moderna announced that Health Canada had authorized the use of its Omicron-targeting bivalent COVID-19…
On Feb. 15, 2023, Moderna announced it will continue to offer its COVID-19 vaccines for free, even after…
On Jan. 17, 2023, Moderna announced positive topline data from its ConquerRSV Phase 3 pivotal efficacy trial of…
On Dec. 21, 2022, Moderna announced the the finalization of a strategic partnership with the United Kingdom (UK)…
On Dec. 16, 2022, Moderna announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use…
On Dec. 8, 2022, Moderna announced it had received emergency use authorization from the U.S. Food and Drug…
On Nov. 14, 2022, Moderna announced that both of Moderna’s bivalent Omicron-targeting booster candidates (mRNA-1273.214 and mRNA-1273.222) trigger…
On Nov. 4, 2022, Moderna announced that Health Canada had authorized the use of its BA.4/BA.5 Omicron-targeting bivalent…
On Oct. 31, 2022, Moderna announced that it had received approval from the Ministry of Health, Labour and…
On Oct. 19, 2022, the U.S. Food and Drug Administration (FDA) recommended the use of the Novavax COVID-19…
On Oct. 19, 2022, Moderna announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…
On Oct. 19, 2022, Moderna announced new clinical data on its bivalent Omicron-containing booster, mRNA-1273.214. Ninety days after…
On Oct. 17, 2022, Moderna and Gavi, the Vaccine Alliance, announced they had mutually agreed to cancel remaining…
On Oct. 12, 2022, Moderna announced that it had received emergency use authorization from the U.S. Food and…
On Sept. 28, 2022, Moderna announced that the European Medicines Agency (EMA) had accepted a variation for the…
On Aug. 23, 2022, Moderna announced that it has completed its submission to the U.S. Food and Drug…
On Aug. 23, 2022, Moderna announced that the Government of Canada had exercised its option to purchase an…
On Aug. 15, 2022, Moderna announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK…
On Aug. 9, 2022, Moderna announced an amendment to its agreement with the European Commission (EC) to convert…
On Jul. 29, 2022, the U.S. Department of Health and Human Services (HHS), in collaboration with the U.S….
On Jul. 22, 2022, Moderna announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…
On Jul. 18, 2022, Moderna announced that the Therapeutic Goods Administration (TGA) in Australia had granted provisional registration…
On Jul. 14, 2022, Moderna announced that Health Canada had approved the use of Moderna’s mRNA COVID-19 vaccine,…
On Jul. 11, 2022, Moderna announced new clinical data on its bivalent Omicron (BA.1) booster candidate, mRNA-1273.214. One…
On Jul. 11, 2022, the National Institute of Allergy and Infectious Diseases (NIAID) launched an early-stage clinical trial…
On Jun. 17, 2022, Moderna announced that it had received emergency use authorization from the U.S. Food and…
On Jun. 8, 2022, Moderna announced new clinical data on its Omicron-containing bivalent COVID booster candidate, mRNA-1273.214, containing…
On Jun. 2, 2022, Moderna announced an agreement with the European Commission (EC) to amend their originally agreed…